LIMN — Liminatus Pharma Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Annual income statement for Liminatus Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | C2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.001 | 3.14 | 1.87 | 2.3 | 2.91 |
| Operating Profit | -0.001 | -3.14 | -1.87 | -2.3 | -2.91 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.001 | 4.37 | 10.8 | -1.19 | -2.89 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.001 | 4.37 | 10.2 | -1.23 | -2.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.001 | 4.37 | 10.2 | -1.23 | -2.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.001 | 4.37 | 10.2 | -1.23 | -2.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0 | 0.144 | 0.298 | -0.153 | -0.404 |
| Dividends per Share |